Clinical bottom line
Recent advancements in melanoma surveillance and adjuvant therapy have significantly improved outcomes for patients with high-risk melanoma. Enhanced surveillance strategies, including imaging and biomarker assessments, aim to detect recurrences early. Adjuvant therapies, particularly immune checkpoint inhibitors and targeted therapies, have demonstrated efficacy in reducing recurrence risk and improving survival in patients with resected stage III and IV melanoma. Clinicians should tailor surveillance and treatment plans based on individual risk factors and emerging evidence.
What the evidence shows
Current guidelines recommend a risk-based approach to melanoma surveillance, incorporating clinical examination and imaging for patients with high-risk features. A systematic review by Francken et al. (2020) highlights the role of imaging modalities such as PET-CT and MRI in detecting early recurrences, particularly in stage III and IV melanoma [PMID: 32012347].
In terms of adjuvant therapy, immune checkpoint inhibitors, such as pembrolizumab and nivolumab, have shown significant benefits. The KEYNOTE-054 trial demonstrated that pembrolizumab reduced the risk of recurrence in stage III melanoma by 43% compared to placebo [PMID: 29658430]. Similarly, the CheckMate 238 trial found that nivolumab improved recurrence-free survival compared to ipilimumab in resected stage III and IV melanoma [PMID: 28891423].
Targeted therapies, such as the combination of dabrafenib and trametinib, have also been effective in BRAF-mutant melanoma. The COMBI-AD trial reported a 53% reduction in recurrence risk with this combination compared to placebo [PMID: 28891408].
Caveats and uncertainty
While adjuvant therapies have improved outcomes, they are not without side effects. Immune-related adverse events, such as colitis and hepatitis, are associated with immune checkpoint inhibitors and require careful monitoring and management. Targeted therapies can cause pyrexia and fatigue, impacting patient quality of life.
The optimal duration and combination of adjuvant therapies remain areas of active research. Additionally, the role of novel biomarkers in guiding therapy decisions is still under investigation. The variability in individual responses to treatment underscores the need for personalized approaches.
The cost and accessibility of advanced imaging and therapies may also limit their widespread adoption, particularly in resource-limited settings.
How this may change practice
The integration of advanced surveillance techniques and adjuvant therapies into melanoma management protocols has the potential to improve patient outcomes significantly. Clinicians should consider these options for patients with high-risk melanoma, balancing the benefits against potential side effects and individual patient factors.
As evidence continues to evolve, treatment guidelines may increasingly emphasize personalized approaches, incorporating genetic and biomarker data to tailor surveillance and therapy. This shift towards precision medicine in melanoma care could enhance survival rates and quality of life for patients.